Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Monday, February 24, 2014
Compounding Sales Job Opening claiming to be with pharmacy with the largest volume PCCA member under one roof out of 2500 members
MEDICAL SALES (TERRITORY MANAGER) (Cincinnati, Ohio)
If you have Pharmaceutical or Medical Sales experience with physician relationships and looking to add HIGH RESIDUAL INCOME, with greater earning potential, and more independence, look no further.
Established relationships with providers a plus (Podiatry, Pain Management, Orthopedic, Neurology, Family Practice, Internal Medicine, Dermatology, Rheumatology, Sports Medicine). Territory Managers around the nation are taking home $100,000 to over $500,000.00 per year.
If you are marketing transdermal pain cream therapy, wound care, scar care therapy, dermatology, or other compounds and getting paid only minimal dollars per script or less than 24% commission, and you are not pleased with the service your compounding pharmacy is providing you or your providers patients, then I would like to speak to you. This unique opportunity can be a supplement to your existing sales position, while utilizing your current contacts and relationships you can capitalize on unlimited possibilities. We offer a generous and aggressive commission based plan that is aimed at growing an established sales force to market transdermal creams and other products.
The number of deaths from oral pain medications have tripled over the past 10 years. Compounded transdermal pain creams are a safe and effective way to deliver medications through the skin to the soft tissue of the muscle, relieving pain at the site of injury while foregoing the risk of oral pain medications.
Transdermal pain therapy is a 30 billion dollar industry and growing. It is a non-addictive, non-narcotic, non-sedating alternative for pain therapy for patients of all ages. Take advantage of this exciting opportunity that offers the highest commissions throughout our distribution network.
Scripts adjudicate from $200.00 to $13,000.00 in range, and we pay 20-24% in commissions. No caps on prescription amounts, and commissions are on ALL refills. Real time sales rep portal for full viewing of sales data by sales representative and/or distributor, updated every thirty minutes.
We work with a pharmacy that is the largest volume PCCA member under one roof out of 2500 members, compounding with only the highest quality ingredients.
They provide Innovative Compounded Transdermal Pain Management, Wound Care Formulations as well as formulations for Scars and Stretch marks. These creams offer many advantages such as:
• Rapid Onset of Relief
• Targets to Site of Pain
• Customized Formulations for Patient Needs and Made to Order
• Non-Narcotic
• Non-Addictive
• Non-Sedating
• Minimal Systemic Concentration
• Minimal Drug Interaction Risk
• Customed Formulations
• Odorless
• Private/Commercial insurance accepted
EVERY provider treats patients with some sort of pain and they see them EVERY day. Many of these physicians are surgeons who would have the capability to write 2 prescriptions for patients with one being for pain and another for the scars that the patients may want to try and reduce.
If you are interested please attach a resume to J.Massa@scottiedogspine.com or reply with your contact information for additional information.
compensation: Up to and over $100,00 per year.
Established relationships with providers a plus (Podiatry, Pain Management, Orthopedic, Neurology, Family Practice, Internal Medicine, Dermatology, Rheumatology, Sports Medicine). Territory Managers around the nation are taking home $100,000 to over $500,000.00 per year.
If you are marketing transdermal pain cream therapy, wound care, scar care therapy, dermatology, or other compounds and getting paid only minimal dollars per script or less than 24% commission, and you are not pleased with the service your compounding pharmacy is providing you or your providers patients, then I would like to speak to you. This unique opportunity can be a supplement to your existing sales position, while utilizing your current contacts and relationships you can capitalize on unlimited possibilities. We offer a generous and aggressive commission based plan that is aimed at growing an established sales force to market transdermal creams and other products.
The number of deaths from oral pain medications have tripled over the past 10 years. Compounded transdermal pain creams are a safe and effective way to deliver medications through the skin to the soft tissue of the muscle, relieving pain at the site of injury while foregoing the risk of oral pain medications.
Transdermal pain therapy is a 30 billion dollar industry and growing. It is a non-addictive, non-narcotic, non-sedating alternative for pain therapy for patients of all ages. Take advantage of this exciting opportunity that offers the highest commissions throughout our distribution network.
Scripts adjudicate from $200.00 to $13,000.00 in range, and we pay 20-24% in commissions. No caps on prescription amounts, and commissions are on ALL refills. Real time sales rep portal for full viewing of sales data by sales representative and/or distributor, updated every thirty minutes.
We work with a pharmacy that is the largest volume PCCA member under one roof out of 2500 members, compounding with only the highest quality ingredients.
They provide Innovative Compounded Transdermal Pain Management, Wound Care Formulations as well as formulations for Scars and Stretch marks. These creams offer many advantages such as:
• Rapid Onset of Relief
• Targets to Site of Pain
• Customized Formulations for Patient Needs and Made to Order
• Non-Narcotic
• Non-Addictive
• Non-Sedating
• Minimal Systemic Concentration
• Minimal Drug Interaction Risk
• Customed Formulations
• Odorless
• Private/Commercial insurance accepted
EVERY provider treats patients with some sort of pain and they see them EVERY day. Many of these physicians are surgeons who would have the capability to write 2 prescriptions for patients with one being for pain and another for the scars that the patients may want to try and reduce.
If you are interested please attach a resume to J.Massa@scottiedogspine.com or reply with your contact information for additional information.
- Location: Cincinnati, Ohio
- Compensation: Up to and over $100,00 per year.
- Principals only. Recruiters, please don't contact this job poster.
- do NOT contact us with unsolicited services or offers
- Principals only. Recruiters, please don't contact this job poster.
- do NOT contact us with unsolicited services or offers
- quoted from here
L-citrulline Not First Time Medisca Has Been in Trouble With FDA; In 2012, the company was sentenced in U.S. district court for unlawfully selling human growth hormone drugs from China.
Recalled Supplement L-citrulline May Endanger Kids, FDA Warns
New York-based compounding firm Medisca recently issued a voluntary recall of certain lot numbers of its L-citrulline products and warned consumers to be on alert for potential problems.
Children are primary users of L-citrulline, an amino acid used to treat genetic disorders found primarily in kids. It is also being studied for use in mild to moderate erectile dysfunction in men.
The FDA reported that several recalled lots of the medication actually contained no L-citrulline. Instead of L-citrulline, the lots contained another drug, N- acetyl-leucine, which is prescribed to treat vertigo.
Eight of the recalled lot numbers were sent to hospitals and pharmacies across the country. The FDA did not identify specifically who received the bad lots.
After receiving reports of several adverse events linked to the faulty drug, the FDA recently released a warning.
“Subpotent L-citrulline in patients with certain urea cycle defects can lead to high ammonia levels, which is serious and potentially life-threatening,” the FDA said.
Several Children Already Affected by Faulty Supplements
At least half a dozen children have already reported health problems from taking what they thought was L-citralline.This amino acid clears excess ammonia from the blood. Too much ammonia in the blood can lead to brain damage and in serious cases, even death.
Cynthia LeMons, the executive director of the National Urea Cycle Disorders Foundation told NBC News that one girl sustained a significant loss of her hair, which came out in clumps, and suffered stomach pains because of excessive ammonia in her blood. The girl had to be hospitalized.
Medisca ships L-citrulline in powder form. From that, the drug can be sold as a power or be compounded into tablets, capsules or liquids.
Most at risk from the faulty supplements are children who take them because of rare urea cycle disorders, which effects 2,000 to 2,500 U.S. kids. While other companies also supply the drug, Medisca is the main supplier.
Parents, caregivers and doctors of patients who take L-citrulline are urged to call their healthcare providers immediately if they have concerns about the product.
The FDA is also asking healthcare professionals to be aware of these recalled lots numbers and not administer them to patients. It also instructs them to return all unused products to Medisca.
The FDA and Troubled Compounding Pharmacies
This is not the first time Medisca has had trouble with its products. In 2012, the company was sentenced in U.S. district court for unlawfully selling human growth hormone drugs from China.The compounding firm was ordered to pay a $15,000 fine and lost $1.7 million.
Other compounding companies have also come under fire for putting the public at risk. In 2012, a contaminated steroid distributed by the New England Compounding Center used to treat back pain resulted in almost 1,000 cases of fungal meningitis which resulted in 64 deaths.
This incident prompted the FDA to pass stricter regulations on compounding pharmacies. In January of 2014, these companies began registering with the FDA – including Medisca.
Medisca released a statement saying the faulty L-citrulline products “represent a potential health hazard. These lots should not be used for any pourpose.”
The FDA said that all adverse reactions should be reported to the agency at MedWatch.
Trial begins for Iowa City compounding pharmacist-Micheal Stein Owner of Pharmacy Matters. Stein is accused of fraud
DES MOINES, Iowa (AP) — A trial is starting for an Iowa pharmacist accused of fraudulently billing an insurance company for life-saving drugs sent to hemophilia patients.
Michael Stein, the owner of Pharmacy Matters in Iowa City, has pleaded not guilty to 15 counts of health care fraud. Jury selection began Monday in federal court in Des Moines.
Prosecutors contend Stein billed Wellmark for expensive drugs to treat hemophilia, when his pharmacy actually did little work in dispensing those drugs. They say his pharmacy acted as a "pass-through entity" for Florida companies, giving them access to the Blue Cross and Blue Shield network.
Stein's attorneys say the case is a contract dispute between a pharmacist and an insurer. They say reasonable minds disagree about whether Stein provided a service for which he could bill Wellmark.
quoted from here
Michael Stein, the owner of Pharmacy Matters in Iowa City, has pleaded not guilty to 15 counts of health care fraud. Jury selection began Monday in federal court in Des Moines.
Prosecutors contend Stein billed Wellmark for expensive drugs to treat hemophilia, when his pharmacy actually did little work in dispensing those drugs. They say his pharmacy acted as a "pass-through entity" for Florida companies, giving them access to the Blue Cross and Blue Shield network.
Stein's attorneys say the case is a contract dispute between a pharmacist and an insurer. They say reasonable minds disagree about whether Stein provided a service for which he could bill Wellmark.
quoted from here
Pegasus Laboratories, Inc. has Sued Lowlite Investments Inc (dba Olympia Compounding Pharmacy) for Patent Infringement
U.S. District Court
Middle District of Florida (Orlando)
CIVIL DOCKET FOR CASE #: 6:14-cv-00051-RBD-TBS
Pegasus Laboratories, Inc. v. Lowlite Investments, Inc. Assigned to: Judge Roy B. Dalton, Jr. Referred to: Magistrate Judge Thomas B. Smith Cause: 35:271 Patent Infringement | Date Filed: 01/10/2014 Jury Demand: Plaintiff Nature of Suit: 830 Patent Jurisdiction: Federal Question |
| Plaintiff | ||
| Pegasus Laboratories, Inc. | represented by | Margaret Diane Mathews Akerman Senterfitt, LLP Suite 1700 401 E Jackson St Tampa, FL 33602-5250 813/223-7333 Fax: 813/223-2837 Email: margaret.mathews@akerman.com LEAD ATTORNEY ATTORNEY TO BE NOTICED Robert Cameron Garrison Lathrop & Gage, LLP Suite 2200 2345 Grand Boulevard Kansas City, MO 64108 816/292-2000 Fax: 816/292-2001 Email: cgarrison@lathropgage.com LEAD ATTORNEY PRO HAC VICE ATTORNEY TO BE NOTICED |
V. | ||
| Defendant | ||
| Lowlite Investments, Inc. doing business as Olympia Compounding Pharmacy | ||
| Date Filed | # | Docket Text |
|---|---|---|
| 01/10/2014 | 1 | COMPLAINT against Lowlite Investments, Inc. with Jury Demand (Filing fee $ 400, receipt number ORL30922) filed by Pegasus Laboratories, Inc. (Attachments: # 1 Exhibits A, B & C, # 2 Exhibits D & E, # 3 Civil Cover Sheet)(IGC) (Entered: 01/13/2014) |
| 01/10/2014 | 2 | SUMMONS issued as to Lowlite Investments, Inc. (issued at intake) (IGC) (Entered: 01/13/2014) |
| 01/13/2014 | 3 | PATENT Report sent to Alexandria, VA. (Attachments: # 1 Complaint, # 2 Exhibits A, B & C, # 3 Exhibits D & E, # 4 Civil Cover Sheet) (IGC) (Entered: 01/13/2014) |
| 01/14/2014 | 4 | ORDER that the Clerk of the Court is directed to REASSIGN this case to another District Judge for all further proceedings. Signed by Senior Judge G. Kendall Sharp on 1/14/2014. (DB) (Entered: 01/14/2014) |
| 01/14/2014 | 5 | Case Reassigned to Judge Roy B. Dalton, Jr.. New case number: 6:14-cv-51-Orl-37TBS. Senior Judge G. Kendall Sharp no longer assigned to the case. (IGC) (Entered: 01/14/2014) |
| 01/15/2014 | 6 | RELATED CASE ORDER AND NOTICE of designation under Local Rule 3.05 - track 2. Notice of pendency of other actions due by 1/29/2014. Signed by Deputy Clerk on 1/15/2014. (Attachments: # 1, # 2, # 3 )(VMF) (ctp) (Entered: 01/15/2014) |
| 01/15/2014 | 7 | INTERESTED PERSONS ORDER Certificate of interested persons and corporate disclosure statement due by 1/29/2014. Signed by Judge Roy B. Dalton, Jr. on 1/15/2014. (VMF) (ctp) (Entered: 01/15/2014) |
| 01/17/2014 | 8 | MOTION for R. Cameron Garrison to appear pro hac vice by Pegasus Laboratories, Inc.. (Mathews, Margaret) Motions referred to Magistrate Judge Thomas B. Smith. (Entered: 01/17/2014) |
| 01/17/2014 | 9 | ORDER granting 8 motion for R. Cameron Garrison to appear pro hac vice on behalf of Plaintiff. Signed by Magistrate Judge Thomas B. Smith on 1/17/2014. (Smith, Thomas) (Entered: 01/17/2014) |
| 01/22/2014 | 10 | ***PRO HAC VICE FEES paid and Special Admission Attorney Certification Form filed by attorney R. Cameron Garrison appearing on behalf of Pegasus Laboratories, Inc. (Filing fee $10, receipt number ORL31135) Related document: 8 MOTION for R. Cameron Garrison to appear pro hac vice. (IGC) (Entered: 01/22/2014) |
| 01/29/2014 | 11 | CERTIFICATE of Interested Persons and Corporate Disclosure Statement re: 7 Interested Persons Order by Pegasus Laboratories, Inc. identifying Corporate Parent PBI-Gordon Corporation for Pegasus Laboratories, Inc. (Mathews, Margaret) Modified on 1/30/2014 (LMM). Modified on 1/30/2014 (LMM). (Entered: 01/29/2014) |
| 01/29/2014 | 12 | NOTICE of compliance re 9 Order on motion to appear pro hac vice by Pegasus Laboratories, Inc. (Garrison, Robert) (Entered: 01/29/2014) |
| 01/30/2014 | 13 | Remark: Doc. 11 has been reviewed. Signed by Judge Roy B. Dalton, Jr. on 1/30/2014. (LLM) (Entered: 01/30/2014) |
Pegasus Laboratories voluntarily dismisses federal complaint against Weatherford Compounding Pharmacy
| 01/10/2014 | 10 | ORDER ADMINISTRATIVELY CLOSING CASE: Parties shall file stipulation of dismissal by 2/10/2014. Signed by District Judge Carlos Murguia on 1/10/2014. (mm) (Entered: 01/10/2014) |
| 01/28/2014 | 11 | NOTICE OF VOLUNTARY DISMISSAL by Pegasus Laboratories, Inc. (Garrison, Robert) (Entered: 01/28/2014) |
What's New on the FDA Drugs Site --from FDA 2/21/2014
- Guidance for Industry: E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility (updated)
- Drug Firm Annual Registration Status (updated)
- Drug Firm Annual Registration Status Download File (updated)
- Guidance for Industry: New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products (PDF - 248KB)
- Food and Drug Administration/Xavier University PharmaLink Conference—Leadership in a Global Supply Chain, March 19, 2014 and March 21, 2014, Xavier University, 3800 Victory Pkwy.,Cincinnati, OH 45207. Meeting information
- National Drug Code Directory
- Over-The-Counter Drug Monograph System - Past, Present and Future; Public Hearing, March 25-26, 2014, FDA White Oak Campus, 10903 New Hampshire Avenue, Bldg. 31, Room 1503 (Great Room), Silver Spring, MD. Meeting information
- Safe Use Initiative: Funding and Support (updated)
Subscribe to:
Posts (Atom)